Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status

BACKGROUND: Cells with homologous recombination (HR) deficiency, most notably caused by mutations in the BRCA1 or BRCA2 genes, are sensitive to PARP inhibition. Microsatellite instability (MSI) accounts for 10-15% of colorectal cancer (CRC) and is hypothesized to lead to HR defects due to altered ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Genther Williams, Sybil M, Kuznicki, Apryle M, Andrade, Paula, Dolinski, Brian M, Elbi, Cem, O’Hagan, Ronan C, Toniatti, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326439/
https://www.ncbi.nlm.nih.gov/pubmed/25685067
http://dx.doi.org/10.1186/s12935-015-0162-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326439/
https://www.ncbi.nlm.nih.gov/pubmed/25685067
http://dx.doi.org/10.1186/s12935-015-0162-8

Ejemplares similares